<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012111710585N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-03-20</date_registration>
      <primary_sponsor>The vice chancellor for research,The medical school of Tehran University of Medical Science</primary_sponsor>
      <public_title>Intravenous Morphine sulfate versus  nebulized Fentanyl  in patients with acute pain.</public_title>
      <acronym></acronym>
      <scientific_title>Effect of nebulized Fentanyl in relief pain due to acute limb trauma and comparing it with intravenous Morphine sulfate.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-11-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/11054</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Other design features: In this study we had two similar packages of drugs that had prepared with study headmaster. Both of them included two 10 milliliter syringes that had filled with clear liquid by headmaster of study; Patients randomly treated with one of the packages that randomized by 4 digits block manner.&#13;
Our study is triple blind because researcher, patients and analyzer of results did not know anything about contents of each package.</study_design>
      <phase>2</phase>
      <hc_freetext>Acute limb trauma.</hc_freetext>
      <i_freetext>Intervention 1: In group 1 or intervention group patients received drug and placebo in 2 syringes that were filled by study headmaster. Both of the syringes contained 10 milliliter of clear liquid.&#13;
Syringe number 1 contained 10 milliliters  distilled water as placebo for intravenous injection by dose of 0.1 milliliter/kilogram of body weight within 1 minute.&#13;
Syringe number 2 contained 10 milliliter of 50 Micro gram/milliliter of Fentanyl that build in Iranian drug industry (Daroupakhsh or Abureihan). Fentanyl prescribed via nebulizer by dose of 0.08 milliliter/kilogram equal to dose of four Micro gram/Kilogram within 5 minutes after intravenous drug.&#13;
Patients had been monitored for change in pain scale by 10 number Numerical Pain Score (NRS) and side effects in 5, 10, 15, 30 and 60 minutes after receiving drug via nebulizer  by asking them with a questionnaire.&#13;
Patients who had not reported decrease in pain scale at least 3 number, 15 minutes after nebulized drug, received 1 milligram rescue dose of morphine sulfate intravenously at times 15 and 30 minutes after nebulized drug. Intervention 2: In group 2 or control group patients received drugs in 2 syringes that were filled by study headmaster and both of them contained 10 milliliters of clear liquid.&#13;
Syringe number 1 contains 10 milliliters of morphine sulfate; build in Iranian drug industry (Daroupakhsh or Abureihan) that diluted to 1 milligram/milliliter  for intravenous injection. Intra venous Morphine sulfate prescribed by dose of 0.1 milliliter/kilogram equal to 0.1 milligram/kilogram of body weight within 1 minute.&#13;
Syringe number 2 contains 10 milliliter of distilled water as placebo for prescription via nebulizer  by dose of 0.08 milliliter/kilogram within 5 minutes after intravenous drug.&#13;
Patients had been monitored for change in pain scale by 10 number Numerical Pain Score (NRS) and side effects in 5, 10, 15, 30 and 60 minutes after receiving drug via nebulizer by asking them via questionnaire.&#13;
Patients who had not reported decrease in pain scale at least 3 number, 15 minutes after drugs, received 1 milligram rescue dose of Morphine sulfate intravenously.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Shervin Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency department of Imam Khomeini's Hospital, Keshavarz Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6690 4848</telephone>
        <email>shfarahmand@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Shervin Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency department of Imam Khomeini's Hospital, Keshavarz Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6690 4848</telephone>
        <email>shfarahmand@sina.tums .ac.ir</email>
        <affiliation>Tehran University of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: all patients who presented to our ED and were  complaining pain due to acute limb trauma with severity index of pain at least 5 of 10 in Numerical Pain Score (NRS).&#13;
Exclusion criteria: special group of patients (pregnant, breast feeding); history of respiratory disease such as asthma; patients who were receiving neuroleptic drugs; patients with chronic pain, opium or alcohol addiction or chronic use of analgesics.</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S40, S41, </hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Superficial injury to shoulder and upper arm, Open wound of shoulder and upper arm, fracture of shoulder and upper arm, Dislocation, sprain and strain of joints and ligaments of shoulder girdle, Superficial injury of forearm, Open wound of forearm, Fractu</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In group 1 or intervention group patients received drug and placebo in 2 syringes that were filled by study headmaster. Both of the syringes contained 10 milliliter of clear liquid.&#13;
Syringe number 1 contained 10 milliliters  distilled water as placebo for intravenous injection by dose of 0.1 milliliter/kilogram of body weight within 1 minute.&#13;
Syringe number 2 contained 10 milliliter of 50 Micro gram/milliliter of Fentanyl that build in Iranian drug industry (Daroupakhsh or Abureihan). Fentanyl prescribed via nebulizer by dose of 0.08 milliliter/kilogram equal to dose of four Micro gram/Kilogram within 5 minutes after intravenous drug.&#13;
Patients had been monitored for change in pain scale by 10 number Numerical Pain Score (NRS) and side effects in 5, 10, 15, 30 and 60 minutes after receiving drug via nebulizer  by asking them with a questionnaire.&#13;
Patients who had not reported decrease in pain scale at least 3 number, 15 minutes after nebulized drug, received 1 milligram rescue dose of morphine sulfate intravenously at times 15 and 30 minutes after nebulized drug.</i_keyword>
      <i_keyword>In group 2 or control group patients received drugs in 2 syringes that were filled by study headmaster and both of them contained 10 milliliters of clear liquid.&#13;
Syringe number 1 contains 10 milliliters of morphine sulfate; build in Iranian drug industry (Daroupakhsh or Abureihan) that diluted to 1 milligram/milliliter  for intravenous injection. Intra venous Morphine sulfate prescribed by dose of 0.1 milliliter/kilogram equal to 0.1 milligram/kilogram of body weight within 1 minute.&#13;
Syringe number 2 contains 10 milliliter of distilled water as placebo for prescription via nebulizer  by dose of 0.08 milliliter/kilogram within 5 minutes after intravenous drug.&#13;
Patients had been monitored for change in pain scale by 10 number Numerical Pain Score (NRS) and side effects in 5, 10, 15, 30 and 60 minutes after receiving drug via nebulizer by asking them via questionnaire.&#13;
Patients who had not reported decrease in pain scale at least 3 number, 15 minutes after drugs, received 1 milligram rescue dose of Morphine sulfate intravenously.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score which is reported by patient. Timepoint: Five, 10, 15, 30 and 60 minutes after receiving drugs. Method of measurement: Questionnaire by Numerical Pain Scale(NRS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Respiratory rate. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Patient's Global rating of satisfaction. Timepoint: One hour after receiving drug via nebulizer. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>The period of time between treatment and the onset of  analgesia. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Total dose of  rescue dose of Morphine sulfate. Timepoint: Since 15 minutes after receiving drug via nebulizer. Method of measurement: milligram.</sec_outcome>
      <sec_outcome>The percentage of arterial  Oxygen saturation. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Percent.</sec_outcome>
      <sec_outcome>Systolic and diastolic blood pressure. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: millimeter of mercury.</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Beat per minute.</sec_outcome>
      <sec_outcome>Level of consciousness. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>The number of reported nausea or vomiting. Timepoint: Five, 10, 15, 30, 60 minutes after receiving drugs. Method of measurement: Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The vice chancellor for research,The medical school of Tehran University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-10-11</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Science</contact_name>
        <contact_address>Room 501, floor 5, Central building of Tehran University of Medical Science Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
